These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 10528800)
1. Immunogenicity of the GPGRAFY epitope on synthetic peptides. Chen YH; Yu T; Bai Y; Dierich MP Immunol Lett; 1999 Sep; 69(3):353-4. PubMed ID: 10528800 [No Abstract] [Full Text] [Related]
2. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation. Tian H; Xiao Y; Qin L; Chen YH Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398 [TBL] [Abstract][Full Text] [Related]
3. Induction of high levels of epitope-specific antibodies by epitope/peptide candidate vaccines against human immunodeficiency virus type-1 (HIV-1). Yu T; Bai Y; Dierich MP; Chen YH Microbiol Immunol; 2000; 44(2):105-10. PubMed ID: 10803497 [TBL] [Abstract][Full Text] [Related]
4. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein. Lu Y; Xiao Y; Ding J; Dierich MP; Chen YH Scand J Immunol; 2000 May; 51(5):497-501. PubMed ID: 10792842 [TBL] [Abstract][Full Text] [Related]
5. Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries. Boots LJ; McKenna PM; Arnold BA; Keller PM; Gorny MK; Zolla-Pazner S; Robinson JE; Conley AJ AIDS Res Hum Retroviruses; 1997 Dec; 13(18):1549-59. PubMed ID: 9430247 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1. Lu Y; Xiao Y; Ding J; Dierich M; Chen YH Int Arch Allergy Immunol; 2000 Jan; 121(1):80-4. PubMed ID: 10686512 [TBL] [Abstract][Full Text] [Related]
7. Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli. Bckström M; Holmgren J; Schödel F; Lebens M Gene; 1995 Nov; 165(2):163-71. PubMed ID: 8522171 [TBL] [Abstract][Full Text] [Related]
8. Sculpted immunogens; B-cell epitope optimization using constrained secondary structure libraries. Urban J; Qabar M; Sia C; Klein M; Kahn M Bioorg Med Chem; 1996 May; 4(5):673-6. PubMed ID: 8804532 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice. Cruz LJ; Quintana D; Iglesias E; Garcia Y; Huerta V; Garay HE; Duarte C; Reyes O J Pept Sci; 2000 May; 6(5):217-24. PubMed ID: 10823490 [TBL] [Abstract][Full Text] [Related]
10. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex. Park EJ; Gorny MK; Zolla-Pazner S; Quinnan GV J Virol; 2000 May; 74(9):4183-91. PubMed ID: 10756031 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of synthetic peptides corresponding to various epitopes of the human immunodeficiency virus envelope protein. Zaghouani H; Hall B; Shah H; Bona C Adv Exp Med Biol; 1991; 303():53-62. PubMed ID: 1725238 [No Abstract] [Full Text] [Related]
12. Peptides mimicking selected disulfide loops in HIV-1 gp120, other than V3, do not elicit virus-neutralizing antibodies. Neurath AR; Strick N; Fields R; Jiang S AIDS Res Hum Retroviruses; 1991 Aug; 7(8):657-62. PubMed ID: 1718344 [TBL] [Abstract][Full Text] [Related]
13. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides. Neurath AR; Strick N; Lee ES J Gen Virol; 1990 Jan; 71 ( Pt 1)():85-95. PubMed ID: 1689372 [TBL] [Abstract][Full Text] [Related]
14. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. Gahéry-Ségard H; Pialoux G; Charmeteau B; Sermet S; Poncelet H; Raux M; Tartar A; Lévy JP; Gras-Masse H; Guillet JG J Virol; 2000 Feb; 74(4):1694-703. PubMed ID: 10644339 [TBL] [Abstract][Full Text] [Related]
15. Synthetic peptides representing discontinuous CD4 binding epitopes of HIV-1 gp120 that induce T cell apoptosis and block cell death induced by gp120. Howie SE; Cotton GJ; Heslop I; Martin NJ; Harrison DJ; Ramage R FASEB J; 1998 Aug; 12(11):991-8. PubMed ID: 9707171 [TBL] [Abstract][Full Text] [Related]
16. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Kang CY; Luo L; Wainberg MA; Li Y Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338 [TBL] [Abstract][Full Text] [Related]
17. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein. Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203 [TBL] [Abstract][Full Text] [Related]
18. HIV-1-specific polyclonal and monoclonal antibodies raised with synthetic peptides: characterization and applications. Laman JD; Schellekens MM; Paddenburg D; Tersmette M; Langedijk JP; Boersma WJ; Claassen E Year Immunol; 1993; 7():63-8. PubMed ID: 7690509 [No Abstract] [Full Text] [Related]
19. Antigenicity of three synthetic peptides from the C-terminus of HIV-1 gp 120 correlates with the fragmentation pattern obtained in FAB mass spectrometry. Streckert HJ; Weber C; Müller D Intervirology; 1993; 36(3):128-33. PubMed ID: 7512081 [TBL] [Abstract][Full Text] [Related]
20. Multiepitope polypeptide of the HIV-1 envelope induces neutralizing monoclonal antibodies against V3 loop. Duarte CA; Montero M; Seralena A; Valdés R; Jiménez V; Benítez J; Narciandi E; Madrazo J; Padrón G; Sánchez G AIDS Res Hum Retroviruses; 1994 Mar; 10(3):235-43. PubMed ID: 7517147 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]